Last reviewed · How we verify
NCT06574464: BIGstd
The BIG Score and In-Hospital Trauma Mortality
trial testing BIG SCORE in Multiple Trauma in 563 participants. Completed in 1 January 2024.
1 December 2023
Quick facts
| Lead sponsor | Haseki Training and Research Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 563 |
| Start date | 1 January 2022 |
| Primary completion | 1 December 2023 |
| Estimated completion | 1 January 2024 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- BIG SCORE
- Glasgow coma scale
- Revised Trauma Score
- Injury Severity Score
Conditions studied
- Multiple Trauma — all drugs for Multiple Trauma →
- Injury Traumatic — all drugs for Injury Traumatic →
Sponsor
Haseki Training and Research Hospital
Who can join
18 and older, any sex, with Multiple Trauma or Injury Traumatic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study investigated the efficacy and reliability of the BIG score, calculated based on the base deficit (BD), International Normalized Ratio (INR), and Glasgow coma scale (GCS), in comparison with the GCS, Revised trauma score (RTS), and Injury Severity Score (ISS) for predicting in-hospital mortality in adults with multiple-trauma presenting to the emergency department (ED).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Predicting mortality in adults hospitalized with multiple trauma: Can the BIG score estimate risk?
Az A, Söğüt Ö, Özçömlekçi M, Doğan Y, et al · · 2025 · PMID 39775514 · DOI 10.14744/tjtes.2024.92879
Verify or expand the search:
- PubMed search for NCT06574464
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Multiple Trauma
Currently open trials in the same condition.
- NCT04588311 — ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients · Phase 3 · recruiting
- NCT03368092 — Inhaled Dornase Alpha to Reduce Respiratory Failure After Severe Trauma · Phase 3 · recruiting
Other Haseki Training and Research Hospital trials
Trials by the same sponsor.
- NCT07502482 — The Effect of Magnesium on Post-spinal Headaches · not yet recruiting
- NCT07201181 — Maternal Smoking Exposure and Newborn Outcomes: Study Using Urinary Cotinine · not yet recruiting
- NCT07203716 — Preparing Kids for MRI Using VR · NA · not yet recruiting
- NCT07165743 — Evaluation of Fetal Bladder Emptying During the 11-14 Weeks' Ultrasound Examination as a Negative Predictive Marker for · active not recruiting
- NCT07179861 — Comparing Artificial Intelligence and Physicians: A Vignette-Based Study in Pediatric Clinical Decision-Making · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06574464 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Haseki Training and Research Hospital
- Last refreshed: 28 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06574464.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing